Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Feb 2026: Biofourmis's former CEO, who left in Aug 2023, was reported to have been charged in Singapore with falsifying company invoices to inflate revenue; the charges are unproven. CopilotIQ acquired Biofourmis in Oct 2024.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Biofourmis found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No product recalls, FDA safety notices or warning letters involving Biofourmis found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
No notable contract go-lives, terminations or customer disputes involving Biofourmis found in HSH's search of the last 24 months.